Intraseason waning of influenza vaccine protection: Evidence from the US influenza vaccine effectiveness network, 2011-2012 through 2014-2015

Clinical Infectious Diseases

Volumn 64, Issue 5, 2017, Pages 544-550

  Ferdinands, Jill M ^a   Fry, Alicia M ^a   Reynolds, Sue ^a,b   Petrie, Joshua G ^c   Flannery, Brendan ^a   Jackson, Michael L ^d   Belongia, Edward A ^e  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d GROUP HEALTH RESEARCH INSTITUTE   (United States)

^e MARSHFIELD CLINIC   (United States)

Author keywords

Case control studies; Influenza; Influenza vaccine; Vaccine effectiveness

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; HUMAN; INFLUENZA; INFLUENZA A (H3N2); INFLUENZA VACCINATION; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX RATIO; ADOLESCENT; ADULT; AGED; CASE CONTROL STUDY; CHILD; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; SEASON; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SEASONS; UNITED STATES; YOUNG ADULT;

EID: 85018168907     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw816     Document Type: Article

References (33)

1. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 influenza season. MMWR Morb Mortal Wkly Rep 2015; 64:818-25.
2. Centers for Disease Control and Prevention. Summary recommendations: prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2013-14. Available at: http://www.cdc.gov/flu/professionals/acip/2013-summary-recommendations.htm. Accessed 17 July 2014.
3. Centers for Disease Control and Prevention. Seasonal influenza (flu): past weekly surveillance reports. 2016. Available at: http://www.cdc.gov/flu/weekly/pastreports.htm. Accessed 17 July 2016.
4. Centers for Disease Control and Prevention. Seasonal influenza vaccine total doses distributed. Available at: http://www.cdc.gov/flu/professionals/vaccination/vaccinesupply.htm. Accessed January 9, 2017.
5. Kissling E, Valenciano M, Larrauri A, et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill 2013;18(5):pii=20390. Available at: http://www.eurosurveillance.org/View Article.aspx? ArticleId=20390.
6. Pebody R, Andrews N, McMenamin J, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill 2013;18(5):pii=20389. Available at: http://www.eurosurveillance. org/ViewArticle.aspx?ArticleId=20389.
7. Jiménez-Jorge S, de Mateo S, Delgado-Sanz C, et al; Spanish Influenza Sentinel Surveillance System. Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination. BMC Infect Dis 2013; 13:441.
8. Castilla J, Martínez-Baz I, Martínez-Artola V, et al; Primary Health Care Sentinel Network; Network for Influenza Surveillance in Hospitals of Navarre. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill 2013;18(5):pii=20388. Available at: http://www.eurosurveillance. org/ViewArticle.aspx?ArticleId=20388.
9. Sullivan SG, Komadina N, Grant K, Jelley L, Papadakis G, Kelly H. Influenza vaccine effectiveness during the 2012 influenza season in Victoria, Australia: influences of waning immunity and vaccine match. J Med Virol 2014; 86:1017-25.
10. Andrews N, McMenamin J, Durnall H, et al. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results. Euro Surveill 2014; 19:5-13.
11. Kissling E, Nunes B, Robertson C, et al; I-MOVE Case-Control Study Team. I-MOVE multicenter case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? Euro Surveill. 2016;21(16):pii=30201. DOI: http://dx.doi. org/10.2807/1560-7917.ES.2016.21.16.30201.
12. McLean HQ, Thompson MG, Sundaram ME, et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis 2014; 211:1529-40.
13. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 2014; 58:319-27.
14. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A(H3N2) illness in children and older adults during a single season. Vaccine 2015; 33:246-51.
15. Petrie JG, Ohmit SE, Truscon R, et al. Modest waning of influenza vaccine efficacy and antibody titers during the 2007-2008 influenza season. J Infect Dis 2016; 214:1142-9.
16. Thompson MG, Naleway A, Fry AM, et al. Effects of repeated annual inactivated influenza vaccination among healthcare personnel on serum hemagglutinin inhibition antibody response to A/Perth/16/2009 (H3N2)-like virus during 2010-11. Vaccine 2016; 34:981-8.
17. Sasaki S, He XS, Holmes TH, et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One 2008; 3:e2975.
18. Huijskens E, Rossen J, Mulder P, et al. Immunogenicity, boostability, and sustainability of the immune response after vaccination against influenza A virus (H1N1) 2009 in a healthy population. Clin Vaccine Immunol 2011; 18:1401-5.
19. Künzel W, Glathe H, Engelmann H, Van Hoecke C. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine 1996; 14:1108-10.
20. McLean HQ, Thompson MG, Sundaram ME, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis 2014; 59:1375-85.
21. Petrie JG, Ohmit SE, Johnson E, Truscon R, Monto AS. Persistence of antibodies to influenza hemagglutinin and neuraminidase following one or two years of influenza vaccination. J Infect Dis 2015; 212:1914-22.
22. Talbot HK, Coleman LA, Zhu Y, et al. Factors associated with maintenance of antibody responses to influenza vaccine in older, community-dwelling adults. BMC Infect Dis 2015; 15:195.
23. Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis 2008; 197:490-502.
24. Song JY, Cheong HJ, Noh JY, et al. Long-term immunogenicity of the influenza vaccine at reduced intradermal and full intramuscular doses among healthy young adults. Clin Exp Vaccine Res 2013; 2:115-9.
25. Song JY, Cheong HJ, Noh JY, et al. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine. J Med Virol 2013; 85:1591-7.
26. Song JY, Cheong HJ, Hwang IS, et al. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine 2010; 28:3929-35.
27. O'Hagan JJ, Hernán MA, Walensky RP, Lipsitch M. Apparent declining efficacy in randomized trials: examples of the Thai RV144 HIV vaccine and South African CAPRISA 004 microbicide trials. AIDS 2012; 26:123-6.
28. Kuntz KM, Goldie SJ. Assessing the sensitivity of decision-analytic results to unobserved markers of risk: defining the effects of heterogeneity bias. Med Decis Making 2002; 22:218-27.
29. White MT, Griffin JT, Drakeley CJ, Ghani AC. Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials. Malar J 2010; 9:82.
30. Smith PG, Rodrigues LC, Fine PE. Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int J Epidemiol 1984; 13:87-93.
31. Farrington CP. The measurement and interpretation of age-specific vaccine efficacy. Int J Epidemiol 1992; 21:1014-20.
32. Kanapathipillai R, Henao Restrepo AM, Fast P, et al. Ebola vaccine-an urgent international priority. N Engl J Med 2014; 371:2249-51.
33. Centers for Disease Control and Prevention. Influenza vaccination coverage estimates by month by influenza season among adults, United States. 2015. Available at: http://www.cdc.gov/flu/images/fluvaxview/sep-2014/nfid-2014-figure3.gif. Accessed 14 January 2015.